TY - JOUR
T1 - Longitudinal Plasma Metabolome Patterns and Relation to Kidney Function and Proteinuria in Pediatric CKD
AU - CKD Biomarkers Consortium
AU - Lee, Arthur M.
AU - Xu, Yunwen
AU - Hu, Jian
AU - Xiao, Rui
AU - Hooper, Stephen R.
AU - Hartung, Erum A.
AU - Coresh, Josef
AU - Rhee, Eugene P.
AU - Vasan, Ramachandran S.
AU - Kimmel, Paul L.
AU - Warady, Bradley A.
AU - Furth, Susan L.
AU - Denburg, Michelle R.
AU - Abraham, Alison
AU - Anderson, Amanda
AU - Ballard, Shawn
AU - Bonventre, Joseph
AU - Clish, Clary
AU - Collins, Heather
AU - Coca, Steven
AU - Whitehead, Krista
AU - Deo, Rajat
AU - Denburg, Michelle
AU - Dubin, Ruth
AU - Feldman, Harold I.
AU - Ferket, Bart S.
AU - Foster, Meredith
AU - Furth, Susan
AU - Ganz, Peter
AU - Gossett, Daniel
AU - Grams, Morgan
AU - Greenberg, Jason
AU - Gutiérrez, Orlando M.
AU - Hostetter, Tom
AU - Inker, Lesley A.
AU - Ix, Joachim
AU - Xie, Dawei
AU - Klein, Jon
AU - Levey, Andrew S.
AU - Massaro, Joseph
AU - McMahon, Gearoid
AU - Mifflin, Theodore
AU - Nadkarni, Girish N.
AU - Parikh, Chirag
AU - Ramachandran, Vasan S.
AU - Rebholz, Casey
AU - Rhee, Eugene
AU - Rovin, Brad
AU - Sarnak, Mark
AU - Sabbisetti, Venkata
N1 - Publisher Copyright:
Copyright © 2024 by the American Society of Nephrology.
PY - 2024/7
Y1 - 2024/7
N2 - Background Understanding plasma metabolome patterns in relation to changing kidney function in pediatric CKD is important for continued research for identifying novel biomarkers, characterizing biochemical pathophysiology, and developing targeted interventions. There are a limited number of studies of longitudinal metabolomics and virtually none in pediatric CKD. Methods The CKD in Children study is a multi-institutional, prospective cohort that enrolled children aged 6 months to 16 years with eGFR 30-90 ml/min per 1.73 m2. Untargeted metabolomics profiling was performed on plasma samples from the baseline, 2-, and 4-year study visits. There were technologic updates in the metabolomic profiling platform used between the baseline and follow-up assays. Statistical approaches were adopted to avoid direct comparison of baseline and follow-up measurements. To identify metabolite associations with eGFR or urine protein-creatinine ratio (UPCR) among all three time points, we applied linear mixed-effects (LME) models. To identify metabolites associated with time, we applied LME models to the 2- and 4-year follow-up data. We applied linear regression analysis to examine associations between change in metabolite level over time (Δlevel) and change in eGFR (ΔeGFR) and UPCR (ΔUPCR). We reported significance on the basis of both the false discovery rate (FDR) <0.05 and P < 0.05. Results There were 1156 person-visits (N: baseline=626, 2-year=254, 4-year=276) included. There were 622 metabolites with standardized measurements at all three time points. In LME modeling, 406 and 343 metabolites associated with eGFR and UPCR at FDR <0.05, respectively. Among 530 follow-up person-visits, 158 metabolites showed differences over time at FDR <0.05. For participants with complete data at both follow-up visits (n=123), we report 35 metabolites with Δlevel-ΔeGFR associations significant at FDR <0.05. There were no metabolites with significant Δlevel-ΔUPCR associations at FDR <0.05. We report 16 metabolites with Δlevel-ΔUPCR associations at P < 0.05 and associations with UPCR in LME modeling at FDR <0.05. Conclusions We characterized longitudinal plasma metabolomic patterns associated with eGFR and UPCR in a large pediatric CKD population. Many of these metabolite signals have been associated with CKD progression, etiology, and proteinuria in previous CKD Biomarkers Consortium studies. There were also novel metabolite associations with eGFR and proteinuria detected.
AB - Background Understanding plasma metabolome patterns in relation to changing kidney function in pediatric CKD is important for continued research for identifying novel biomarkers, characterizing biochemical pathophysiology, and developing targeted interventions. There are a limited number of studies of longitudinal metabolomics and virtually none in pediatric CKD. Methods The CKD in Children study is a multi-institutional, prospective cohort that enrolled children aged 6 months to 16 years with eGFR 30-90 ml/min per 1.73 m2. Untargeted metabolomics profiling was performed on plasma samples from the baseline, 2-, and 4-year study visits. There were technologic updates in the metabolomic profiling platform used between the baseline and follow-up assays. Statistical approaches were adopted to avoid direct comparison of baseline and follow-up measurements. To identify metabolite associations with eGFR or urine protein-creatinine ratio (UPCR) among all three time points, we applied linear mixed-effects (LME) models. To identify metabolites associated with time, we applied LME models to the 2- and 4-year follow-up data. We applied linear regression analysis to examine associations between change in metabolite level over time (Δlevel) and change in eGFR (ΔeGFR) and UPCR (ΔUPCR). We reported significance on the basis of both the false discovery rate (FDR) <0.05 and P < 0.05. Results There were 1156 person-visits (N: baseline=626, 2-year=254, 4-year=276) included. There were 622 metabolites with standardized measurements at all three time points. In LME modeling, 406 and 343 metabolites associated with eGFR and UPCR at FDR <0.05, respectively. Among 530 follow-up person-visits, 158 metabolites showed differences over time at FDR <0.05. For participants with complete data at both follow-up visits (n=123), we report 35 metabolites with Δlevel-ΔeGFR associations significant at FDR <0.05. There were no metabolites with significant Δlevel-ΔUPCR associations at FDR <0.05. We report 16 metabolites with Δlevel-ΔUPCR associations at P < 0.05 and associations with UPCR in LME modeling at FDR <0.05. Conclusions We characterized longitudinal plasma metabolomic patterns associated with eGFR and UPCR in a large pediatric CKD population. Many of these metabolite signals have been associated with CKD progression, etiology, and proteinuria in previous CKD Biomarkers Consortium studies. There were also novel metabolite associations with eGFR and proteinuria detected.
KW - CKD
KW - GFR
KW - lipids
KW - metabolism
KW - pediatric nephrology
KW - progression
KW - proteinuria
KW - renal function
KW - renal function decline
UR - http://www.scopus.com/inward/record.url?scp=85198673007&partnerID=8YFLogxK
U2 - 10.2215/CJN.0000000000000463
DO - 10.2215/CJN.0000000000000463
M3 - Article
C2 - 38709558
AN - SCOPUS:85198673007
SN - 1555-9041
VL - 19
SP - 837
EP - 850
JO - Clinical Journal of the American Society of Nephrology
JF - Clinical Journal of the American Society of Nephrology
IS - 7
ER -